Drugs in the Pipeline
Tezepelumab BLA Submitted for Severe Asthma
The BLA submission is supported by data from the PATHFINDER clinical program.
Your search for oral corticosteroids returned 19 results
Drugs in the Pipeline
Dupilumab Under Review for Pediatric Asthma
The submission was based on data from the double-blind, placebo-controlled VOYAGE trial.
Drugs in the Pipeline
Tezepelumab Cuts Exacerbations in Severe Asthma Trial
Tezepelumab is an investigational first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.
Drugs in the Pipeline
Benralizumab Reduces OCS Use in Severe Asthma Trial
Findings from a phase 3b trial showed that a majority of patients with severe eosinophilic asthma treated with benralizumab (Fasenra; AstraZeneca), an interleukin-5 antagonist, were able to eliminate or reduce oral corticosteroid (OCS) use. The open-label, single-arm PONENTE trial assessed the efficacy and safety of reducing OCS use after initiating treatment with benralizumab in nearly…
Dermatological Disorders, Drugs in the Pipeline
Dupilumab Gets Priority Review for Atopic Dermatitis in Patients Aged 6 to 11 Years
Dupixent, an interleukin-4 receptor alpha antagonist, is currently approved for moderate to severe atopic dermatitis in patients ≥12 years old who are not adequately controlled with topical prescription therapies or when they are not advisable.
Drugs in the Pipeline
Oral Tyrosine Kinase Inhibitor Effective in Severe Asthma Trial
Treatment with masitinib, a selective tyrosine kinase inhibitor, significantly reduces the rate of severe asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids, according to data from a phase 3 study.
Drugs in the Pipeline
Dupilumab Gets Priority Review for Adolescent Atopic Dermatitis
Dupixent is also being assessed in other allergic/inflammatory conditions, including pediatric atopic dermatitis, pediatric asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, grass allergy, and peanut allergy.
Drugs in the Pipeline
Tezepelumab Gets Breakthrough Therapy Designation for Severe Asthma
The designation was based on data from the Phase 2b PATHWAY trial that evaluated 3 doses of tezepelumab as add-on therapy in patients with a history of asthma exacerbations and uncontrolled asthma receiving inhaled corticosteroids/long-acting β-agonist with or without oral corticosteroids and additional asthma controllers vs placebo.
Drugs in the Pipeline
Rituxan Granted Priority Review for Rare Autoimmune Disease
The disease can be life threatening. Phase 3 study results released last March demonstrated Rituxan substantialy improved pemphigus vulgaris remission rates and successful tapering.
Drugs in the Pipeline
Dupilumab Beneficial for Patients with Severe Steroid-Dependent Asthma
Consistent reductions in asthma attacks and improvements in lung function across a broad population of uncontrolled asthma patients.
